WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Highlights of Asian Cup 2022R&D seen as key to success of private firmsEnterprises bullish on supply chain expoXi Awarded Order of South AfricaHainan expands visaChinese mainland resumes import of rockfish from TaiwanXi Story: A Champion of Closer PeopleZhang primed for shot at historyDecade after divorce, woman finds new life on two wheelsClean energy key to CO2 goals